Form 8-K - Current report:
SEC Accession No. 0001641172-25-018403
Filing Date
2025-07-09
Accepted
2025-07-09 16:15:51
Documents
16
Period of Report
2025-07-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 50202
2 EX-4.1 ex4-1.htm EX-4.1 122649
3 EX-10.1 ex10-1.htm EX-10.1 74003
4 EX-10.2 ex10-2.htm EX-10.2 46400
5 GRAPHIC ex10-2_001.jpg GRAPHIC 4429
  Complete submission text file 0001641172-25-018403.txt   522728

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE zvsa-20250708.xsd EX-101.SCH 3011
7 XBRL LABEL FILE zvsa-20250708_lab.xml EX-101.LAB 34239
8 XBRL PRESENTATION FILE zvsa-20250708_pre.xml EX-101.PRE 22356
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3705
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 251113760
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)